XERS News and Press, Xeris Pharmaceuticals Inc.

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...

2024-05-30 10:29:56 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Pharmaceuticals Q1 ...

XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants normalized TSH/T4 levels using 45% less drug than would be needed for their daily oral dose ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...

2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....

2024-05-09 12:49:14 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Conference Call May 09, 2024, 08:30 ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Cal...

2024-05-09 07:16:01 ET More on Xeris Pharmaceuticals Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Pharmaceuticals Q1 2024 Earnings Preview Xeris gains as Oppenheimer highlights drug techno...

Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide ...

2024-05-08 11:41:28 ET More on Xeris Pharmaceuticals Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris gains as Oppenheimer highlights drug technology Xeris Pharmaceuticals Q4 2023 Earnings Pre...